CLPT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLPT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). ClearPoint Neuro's Average Total Inventories for the three months ended in Mar. 2024 was $7.94 Mil. ClearPoint Neuro's Cost of Goods Sold for the three months ended in Mar. 2024 was $3.11 Mil. Hence, ClearPoint Neuro's Days Inventory for the three months ended in Mar. 2024 was 232.54.
The historical rank and industry rank for ClearPoint Neuro's Days Inventory or its related term are showing as below:
During the past 13 years, ClearPoint Neuro's highest Days Inventory was 370.23. The lowest was 247.02. And the median was 311.28.
ClearPoint Neuro's Days Inventory declined from Mar. 2023 (390.83) to Mar. 2024 (232.54).
Inventory Turnover measures how fast the company turns over its inventory within a year. ClearPoint Neuro's Inventory Turnover for the three months ended in Mar. 2024 was 0.39.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. ClearPoint Neuro's Inventory-to-Revenue for the three months ended in Mar. 2024 was 1.04.
The historical data trend for ClearPoint Neuro's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClearPoint Neuro Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Days Inventory | Get a 7-Day Free Trial | 247.50 | 318.75 | 288.28 | 370.23 | 303.80 |
ClearPoint Neuro Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Days Inventory | Get a 7-Day Free Trial | 390.83 | 307.16 | 333.45 | 275.64 | 232.54 |
For the Medical Devices subindustry, ClearPoint Neuro's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's Days Inventory distribution charts can be found below:
* The bar in red indicates where ClearPoint Neuro's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
ClearPoint Neuro's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as
Days Inventory (A: Dec. 2023 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2023 ) | * | Days in Period |
= | ( (9.303 | + | 7.911) | / | 2 ) | / | 10.341 | * | 365 |
= | 8.607 | / | 10.341 | * | 365 | ||||
= | 303.80 |
ClearPoint Neuro's Days Inventory for the quarter that ended in Mar. 2024 is calculated as:
Days Inventory (Q: Mar. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Dec. 2023 ) | + | Total Inventories (Q: Mar. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Mar. 2024 ) | * | Days in Period |
= | ( (7.911 | + | 7.96) | / | 2 ) | / | 3.114 | * | 365 / 4 |
= | 7.9355 | / | 3.114 | * | 365 / 4 | ||||
= | 232.54 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClearPoint Neuro (NAS:CLPT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
ClearPoint Neuro's Inventory Turnover for the three months ended in Mar. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 3.114 | / | 7.9355 | |
= | 0.39 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ClearPoint Neuro's Inventory to Revenue for the three months ended in Mar. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 7.9355 | / | 7.639 | |
= | 1.04 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of ClearPoint Neuro's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Lynnette C Fallon | director | 108 CHERRY HILL DRIVE, BEVERLY MA 01915 |
Linda M. Liau | director | 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075 |
Mazin Sabra | officer: Chief Operating Officer | 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075 |
Joseph Michael Burnett | director, officer: CEO and President | C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618 |
L. Jeremy Stigall | officer: GM, Biologics & Drug Delivery | 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075 |
Danilo D'alessandro | officer: Vice President, Finance | 5 MUSICK, IRVINE CA 92618 |
Harold A Hurwitz | officer: Chief Financial Officer | |
R John Fletcher | director | C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070 |
Girin Pascal E R | director | C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618 |
B Kristine Johnson | director | 366 FERNDALE RD S, WAYZATA MN 55391 |
Timothy T. Richards | director | ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103 |
Matthew B. Klein | director | C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
Marcio Souza | director | C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
Voyager Therapeutics, Inc. | 10 percent owner | 75 HAYDEN AVENUE, LEXINGTON MA 02421 |
Wendelin C Maners | officer: Vice President, Marketing | ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103 |
From GuruFocus
By sperokesalga sperokesalga • 05-18-2023
By Value_Insider Value_Insider • 10-26-2022
By sperokesalga sperokesalga • 04-18-2023
By Marketwired • 08-08-2023
By PurpleRose PurpleRose • 07-12-2022
By sperokesalga sperokesalga • 04-11-2023
By PurpleRose PurpleRose • 08-09-2022
By PurpleRose PurpleRose • 07-26-2022
By Stock market mentor Stock market mentor • 01-11-2023
By Value_Insider Value_Insider • 11-09-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.